• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Spruce Biosciences Recognized as a Bay Area Best Place to Work

    6/6/24 8:00:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRB alert in real time by email

    Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Business Journal have recognized the company as a Best Place to Work in 2024.

    "We are thrilled to be named as a Best Place to Work in the Bay Area, which is a testament to our unwavering dedication to cultivating a mission-driven company culture underlying our core values of trust, innovation, ownership and diversity," said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, Spruce Biosciences. "Our team members are at the heart of our organization, and I'm immensely proud of their dedication and commitment to each other and our stakeholders. This recognition deepens our sense of purpose as we advance our efforts towards delivering transformative treatment options for underserved patient communities."

    Winning organizations were selected from over 230 competing Bay Area companies that have created exceptional workplaces that their employees value highly. The selection process was based on anonymous employee surveys with participation requirements and overall employee engagement score rankings. Applicants were evaluated and ranked across workplace factors and values, including collaborative culture, compensation and benefits offerings, other amenities, and management practice, according to the number of Bay Area employees.

    About Spruce Biosciences

    Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need. Spruce is developing its product candidate, tildacerfont, an oral, second-generation CRF1 receptor antagonist, for the treatment of congenital adrenal hyperplasia (CAH), polycystic ovary syndrome (PCOS) and major depressive disorder (MDD). To learn more, visit www.sprucebio.com and follow us on X @Spruce_Bio, LinkedIn, Facebook and YouTube.

    About 2024 Bay Area Best Places to Work

    Best Places to Work is an innovative publication and awards program produced by the San Francisco Business Times and the Silicon Valley Business Journal. The survey was administered online by the employers and through a service provided by Quantum Workplace, our research partner. The rankings are numeric based on Quantum's scoring process and determined by surveys that went directly to employees who answered a series of questions. By ranking companies and sharing best practices we facilitate idea sharing and help other companies learn from the best.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240606309168/en/

    Get the next $SPRB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPRB

    DatePrice TargetRatingAnalyst
    12/11/2024Mkt Outperform → Mkt Perform
    JMP Securities
    12/11/2024Outperform → Perform
    Oppenheimer
    3/14/2024Buy → Neutral
    Guggenheim
    3/14/2024$9.00 → $2.00Outperform → Market Perform
    Leerink Partners
    3/14/2024$9.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    3/14/2024Buy → Neutral
    Ladenburg Thalmann
    3/14/2024Buy → Neutral
    H.C. Wainwright
    2/21/2024$10.00Buy
    Guggenheim
    More analyst ratings